Next generation sequencing (NGS) also known as high-throughput
sequencing enables scientists to sequence and assemble billions of
short DNA reads. The advent of next generation sequencing
technologies has brought significant changes in the sequencing
process by providing high throughput, speed, flexibility and reduced
sequencing cost over thousand folds. NGS has ability to generate
hundreds of gigabases of nucleotide sequence data in a single
sequencing run. The technology is emerging at a rapid rate due to its
growing adoption in clinical applications as it allows scanning of
whole genomes or targeted genomes in less span of time. In addition,
reduction in cost of sequencing has also expanded the usage of next
generation sequencing in variety of clinical applications. The
technique has imparted its usage in various clinical applications
such as cancer, inherited genetic disorders, HLA typing and
identification of infectious diseases. For instance, NGS has been
used for tracing hospital acquired infections and tuberculosis
outbreaks.
The market for next generation sequencing can be segmented based on
technology, application, end-users and geography. The application
section can be categorized into drug discovery, personalized
medicines, biomarker discovery, diagnostics and others (agriculture,
animal, marine and other studies). The technology section of the
market could be subdivided into sequencing by synthesis, ion
semiconductor sequencing, pyrosequencing, sequencing by ligation and
single molecule real time sequencing. The next generation sequencing
market can also be analyzed based on the end user segment including
hospitals and clinics, research institutions and pharmaceutical and
biotechnology companies.
It is witnessed that more than 65% of the next generation sequencing
revenue is generated from academic institutions, biopharmaceutical
companies and government research institutes. Geographically, the
market is segmented into North America, Europe, Asia-Pacific, Latin
America (LATAM), and Middle East and Africa (MENA). Of all the
geographies, North America accounted for the largest market share in
2014 followed by Europe. However, during the forecast period
Asia-Pacific region is anticipated to record highest growth owing to
market saturation in developed regions. Furthermore, technological
innovation, increasing drug discovery initiatives by healthcare
companies, increasing adoption of innovative models and huge capital
investment by pharmaceutical and biotechnology companies are some of
the key factors expected to drive the growth of next generation
sequencing market in Asia.
Download Report Brochure @
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4774
Currently, the next generation sequencing market is consolidated with
very few market players due to involvement of extremely complicated
technologies and the low target audience for the systems. The
expensive next-generation sequencing systems may exceed a cost of
millions of dollars for installation, maintenance, reagents and
output analysis. Most respondents have suggested sequencing as a
service business rather than an investment for in-house research.
Introduction of bench-top sequencers enabling ease of use to
researchers is also expected to push the market growth further.
Outsourcing sequencing is expected to remain a major contributor to
the revenue generation in the coming years. Response gathered from
research facilities suggest that purchase of these sequencing
platforms may demonstrate actual growth post reduction in the
sequencing costs below USD 1000 as suggested by several
manufacturers. True potential of this technology lies in the
personalized medicine and sequencing genomes of individuals.
Furthermore, increasing initiatives by government bodies for genomics
research would also boost the adoption of high-throughput sequencing
platform.
Pre-Book Full Report @
https://www.transparencymarketresearch.com/checkout.php?rep_id=4774<ype=S
Some of the major players operating in the global NGS market are
Agilent Technologies, Life Sciences Corporation (Roche Holding Ag),
Genomatix Software Gmbh, Illumina, Inc., Gatc Biotech Ag, Dnastar,
Inc., Life Technologies Corporation, Oxford Nanopore Technologies,
Ltd., Perkin Elmer, Inc., Qiagen N.V., Partek Incorporated, Macrogen,
Inc., Knome, Inc., and Genomatix Software Gmbh.
About Us
Transparency Market Research (TMR) is a market intelligence company,
providing global business information reports and services. Our
exclusive blend of quantitative forecasting and trends analysis
provides forward-looking insight for thousands of decision makers.
TMR’s experienced team of analysts, researchers, and consultants,
use proprietary data sources and various tools and techniques to
gather, and analyze information. Our business offerings represent the
latest and the most reliable information indispensable for businesses
to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such
as pharmaceuticals, chemicals, energy, food & beverages,
semiconductors, med-devices, consumer goods and technology. These
reports provide in-depth analysis and deep segmentation to possible
micro levels. With wider scope and stratified research methodology,
TMR’s syndicated reports strive to provide clients to serve their
overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment